| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Pathology and 2 Medicine, Yale University School of Medicine, New Haven, Connecticut
The addition of B-cell lymphoma 2 (Bcl-2) antisense to dacarbazine in the treatment of metastatic melanoma demonstrates improved response rates and progression-free survival when compared with dacarbazine alone. Studies on small cohorts of melanoma patients have shown variability in Bcl-2 expression (60%–96% positive). We performed quantitative analysis of Bcl-2 expression in a large patient cohort to assess the association with outcome.
Tissue microarrays containing intact melanoma specimens representing 402 patients (339 with associated survival data) were analyzed with our AQUA system for automated quantitative analysis. Automated, quantitative analysis uses S100 to define pixels as melanoma (tumor mask) within the array spot and measures intensity of Bcl-2 expression using a Cy5 conjugated antibody within the mask. A continuous index score is generated, which is directly proportional to the number of molecules per unit area. Scores were divided into quartiles and correlated with clinical variables.
High Bcl-2 expression was associated with better outcome in the entire cohort and among metastatic specimens only (P = 0.004 and P = 0.015, respectively). Expression was higher in primary than in metastatic specimens (P < 0.0001). There was no association between Bcl-2 expression and Breslow depth or Clark level.
The diverse results within the literature may be due to use of small cohorts or variability in staining technique. These results suggest studies are needed to evaluate the association between quantitative assessment of Bcl-2 expression and response to Bcl-2 targeting therapy toward the goal of improved response rates to these drugs.
This article has been cited by other articles:
|
|
 |
|
  R. Shen, J. M. G. Taylor, and D. Ghosh Reconstructing tumor-wise protein expression in tissue microarray studies using a Bayesian cell mixture model Bioinformatics, December 15, 2008; 24(24): 2880 - 2886. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Trere, L Montanaro, C Ceccarelli, S Barbieri, G Cavrini, D Santini, M Taffurelli, and M Derenzini Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast Ann. Onc., June 1, 2007; 18(6): 1004 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. McCarthy, K. A. DiVito, M. Sznol, D. Kovacs, R. Halaban, A. J. Berger, K. T. Flaherty, R. L. Camp, R. Lazova, D. L. Rimm, et al. Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma. Clin. Cancer Res., June 15, 2006; 12(12): 3856 - 3863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Berger, D. W. Davis, C. Tellez, V. G. Prieto, J. E. Gershenwald, M. M. Johnson, D. L. Rimm, and M. Bar-Eli Automated Quantitative Analysis of Activator Protein-2{alpha} Subcellular Expression in Melanoma Tissue Microarrays Correlates with Survival Prediction Cancer Res., December 1, 2005; 65(23): 11185 - 11192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Siddiqui, J. Pawelek, T. Handerson, C.-Y. Lin, R. B. Dickson, D. L. Rimm, and R. L. Camp Coexpression of {beta}1,6-N-Acetylglucosaminyltransferase V Glycoprotein Substrates Defines Aggressive Breast Cancers with Poor Outcome Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2517 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. McCarthy, M. Sznol, K. A. DiVito, R. L. Camp, D. L. Rimm, and H. M. Kluger Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer Clin. Cancer Res., July 15, 2005; 11(14): 5188 - 5194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Kluger, D. Chelouche Lev, Y. Kluger, M. M. McCarthy, G. Kiriakova, R. L. Camp, D. L. Rimm, and J. E. Price Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease Cancer Res., July 1, 2005; 65(13): 5578 - 5587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Witkiewicz, S. Varambally, R. Shen, R. Mehra, M. S. Sabel, D. Ghosh, A. M. Chinnaiyan, M. A. Rubin, and C. G. Kleer {alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1418 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Becker, P. thor Straten, and M. H. Andersen The Paradoxical Association between Bcl-2 Expression and Prognosis: Does the Immune System Make the Difference? Cancer Res., April 1, 2005; 65(7): 2983 - 2983. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
